On 28 February 2020, Harbour BioMed announced FDA approval of its Investigational New Drug application for HBM4003, an anti-CTLA-4 antibody and candidate for the treatment of advanced solid tumours.
Permit Required: Full Court Denies Access to Costs Appeal in Carpark Patent Saga
Vehicle Monitoring Systems Pty Limited v SARB Management Group Pty Ltd trading as Database Consultants Australia (Costs) [2024] FCAFC 155 ...